20 (AIDX) Non-Current Deffered Revenue (2024 - 2026)

20's (AIDX) quarterly Non-Current Deffered Revenue came in at $37055.0 in Q1 2026, down 11.39% on a QoQ basis from $41816.0 in Q4 2025.

20 (AIDX) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends

20 (AIDX) has 3 years of Non-Current Deffered Revenue data on file, last reported at $37055.0 in Q1 2026.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $37055.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37055.0 (changed N/A YoY) and the FY2025 annual result came in at $41816.0, down 16.37% from the prior year.
Non-Current Deffered Revenue eased to $37055.0 in Q1 2026, from $41816.0 in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $50000.0 in Q4 2024 to a low of $37055.0 in Q1 2026.
A 3-year average of $42957.0 and a median of $41816.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
The widest YoY moves for Non-Current Deffered Revenue: up 16.37% in 2025, down 16.37% in 2025.
Tracing AIDX's Non-Current Deffered Revenue over 3 years: stood at $50000.0 in 2024, then declined by 16.37% to $41816.0 in 2025, then fell by 11.39% to $37055.0 in 2026.
The last three Non-Current Deffered Revenue figures came in at $37055.0 (Q1 2026), $41816.0 (Q4 2025), and $50000.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Abbott Laboratories	199.44 Bn	193.84 Bn	7.27 Bn	-
2	Stryker	127.32 Bn	123.85 Bn	4.50 Bn	-
3	Medtronic	118.87 Bn	109.65 Bn	6.41 Bn	-
4	Boston Scientific	73.47 Bn	72.93 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.90 Bn	47.65 Bn	1.35 Bn	-
6	Dexcom	34.30 Bn	32.36 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.74 Bn	31.63 Bn	2.18 Bn	-
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	539.34 Mn
9	Steris	23.05 Bn	22.56 Bn	684.20 Mn	-
10	20	5.55 Mn	1.00 Mn	304,727.00	32,924.00

Download Data